Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 16/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 12/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL678787 | 0.88 | HRH3 (0.37) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL8904036 | 0.86 | HRH3 (0.40) | SLC6A3SLC6A2 | |
| SCHEMBL7290184 | 0.84 | MAPT (0.36) | SLC6A3SLC6A2 | |
| SCHEMBL678404 | 0.82 | SLC6A2 (0.30) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7717129 | 0.82 | KMT2A (0.38) | — | |
| SCHEMBL9660602 | 0.82 | SIGMAR1 (0.36) | SLC6A2SLC6A4 | |
| SCHEMBL7427732 | 0.80 | FDPS (0.32) | — | |
| SCHEMBL29100350 | 0.78 | SLC6A3 (0.41) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL17393110 | 0.78 | SLC6A3 (0.34) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6039362 | 0.77 | FDPS (0.34) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2160192-B1 | ANTIMICROBIAL MATERIALS AND COATINGS | COVIDIEN LP (US) | 2018-03-28 | — | — | EP | disclosed |
| US-20170096391-A1 | NOVEL LACTAMS | BIOSIGNAL LIMITED (AU) | 2017-04-06 | — | — | US | disclosed |
| US-9586901-B2 | Lactams | UNILEVER PLC (GB) | 2017-03-07 | — | — | US | disclosed |
| US-8586618-B2 | Furanone compounds and lactam analogues thereof | BIOSIGNAL LIMITED (AU) | 2013-11-19 | — | — | US | disclosed |
| EP-2177226-B1 | Hydroxamate compositions | COVIDIEN LP (US) | 2013-09-18 | — | — | EP | disclosed |
| US-20130190377-A1 | Novel Lactams | BIOSIGNAL LIMITED (AU) | 2013-07-25 | — | — | US | disclosed |
| US-8425972-B2 | Antimicrobial materials and coatings | COVIDIEN LP (US) | 2013-04-23 | — | — | US | disclosed |
| EP-2564859-A1 | Hydroxamate compositions | Covidien LP (US) | 2013-03-06 | — | — | EP | disclosed |
| US-8153741-B2 | Furanone copolymers | TYCO HEALTHCARE GROUP LP (US) | 2012-04-10 | — | — | US | disclosed |
| US-8071691-B2 | Furanone endcapped polymers | TYCO HEALTHCARE GROUP LP (US) | 2011-12-06 | — | — | US | disclosed |
| WO-2002013956-A1 | MEMBRANES AND METHOD OF MANUFACTURE THEREOF | GRADIPORE LIMITED (AU) | 2002-02-21 | — | — | WO | disclosed |
| WO-2002000639-A1 | SYNTHESIS OF CYCLIC COMPOUNDS | UNISEARCH LIMITED (AU) | 2002-01-03 | — | — | WO | disclosed |
| WO-2001076594-A1 | ANTIMICROBIAL COATINGS | UNISEARCH LIMITED (AU) | 2001-10-18 | — | — | WO | disclosed |
| WO-2001068090-A1 | MICROBIAL INHIBITORY COMPOSITIONS | UNISEARCH LIMITED (AU) | 2001-09-20 | — | — | WO | disclosed |
| US-20010020079-A1 | Electrophoresis gels and cross-linking agents for their preparation | THE UNIVERSITY OF MELBOURNE | 2001-09-06 | — | — | US | disclosed |
| WO-2001043739-A1 | INHIBITION OF TWO-COMPONENT SIGNAL TRANSDUCTION SYSTEMS | UNISEARCH LIMITED (AU) | 2001-06-21 | — | — | WO | disclosed |
| US-6197906-B1 | ASSYMETRIC AGENTS SUCH AS (2-METHACRYLOYLOXYETHYL)ACRYLAMIDE, (2-ACRYLOYLOXYETHYL)METHACRYLAMIDE, AND (N-METHYL-N-ACRYLOYLAMINO)ETHYL METHACRYLATE | THE UNIVERSITY OF MELBOURNE (AU) | 2001-03-06 | — | — | US | disclosed |
| EP-0920412-A4 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | UNIV MELBOURNE (AU) | 2000-08-02 | — | — | EP | disclosed |
| EP-0920412-A1 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | THE UNIVERSITY OF MELBOURNE (AU) | 1999-06-09 | — | — | EP | disclosed |
| WO-1998001419-A1 | ELECTROPHORESIS GELS AND CROSS-LINKING AGENTS FOR THEIR PREPARATION | THE UNIVERSITY OF MELBOURNE (AU) | 1998-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190377-A1 | Novel Lactams | SULT1E1, PGLS, Q6ZSR9 | SLC6A3 4395/4885SLC6A2 4441/4885SLC6A4 4658/4885 |
| US-20170096391-A1 | NOVEL LACTAMS | SULT1E1, PGLS, Q6ZSR9 | SLC6A3 4395/4885SLC6A2 4441/4885SLC6A4 4658/4885 |
| US-20010020079-A1 | Electrophoresis gels and cross-linking agents for their preparation | MACF1, ZYX, F12 | SLC6A3 4884/4885SLC6A2 4848/4885SLC6A4 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.